REGENXBIO will host a conference call on August 1st to discuss second quarter 2024 financial results and recent operational highlights. Learn more: https://lnkd.in/dyiUqaQq
REGENXBIO Inc.
Biotechnology Research
Rockville, Maryland 32,163 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO Inc.
Updates
-
July is Disability Pride Month, which celebrates the anniversary of the Americans with Disabilities Act (ADA), which paved the way for greater inclusion and accessibility for people with disabilities. To recognize the month and with the Summer Olympics right around the corner, we were thrilled to welcome Special Olympics Maryland to our headquarters! Last week, we heard from athletes and advocates about their experiences, the challenges they’ve overcome, and their dedication to promoting inclusion and accessibility. We ended the day at Top Golf with athletes from the Frederick County unified golf team. Thank you to all who participated and made this event so special!
-
This month, we celebrated the 2nd anniversary of our Manufacturing Independence Day! This day marks the day when our manufacturing team successfully thawed its first GMP batch in our industry-leading, in-house REGENXBIO Manufacturing Innovation Center. Since this state-of-the-art facility became operational in 2022, we have been able to accelerate the development of our gene therapy candidates and advance our goal of delivering meaningful new medicines to patients. Thank you to our teams of gene therapy and manufacturing experts who bring their passion for helping patients to the REGENXBIO Manufacturing Innovation Center every day.
-
Did you know that June 14th was World Blood Donor Day? Recently, REGENXBIO partnered with the American Red Cross to host our second annual blood drive! These blood drives have the power to save lives and make a real impact on patients in need, a mission close to our hearts. Inspired to donate? Find a local blood drive here: https://lnkd.in/ebwyUut
-
It was great attending Parent Project Muscular Dystrophy’s (PPMD) 30th Annual Conference last week in Orlando to connect and catch up with families, researchers, providers, and fellow industry colleagues. Dr. Naz Dastgir, Clinical Development Lead for our Duchenne program, shared an update on our RGX-202 program and participated in a panel discussion about clinical trials and the development pathway in Duchenne. Congratulations Pat Furlong and PPMD for hosting a great event!
-
This Pride month, we’re celebrating LGBTQIA+ scientists in STEM. Today we highlight Jemma Redmond, an intersex person whose innovation in 3D bioprinting revolutionized medical technology. Learn more about Jemma and other inspiring scientists here: https://lnkd.in/dtzcYFp
-
We’re heading to Orlando this week to join the Duchenne community in celebrating three decades of progress, community and resilience at PPMD’s 30th Annual Conference in Orlando, Florida! Thank you to Pat Furlong and the team at PPMD for your important work to support Duchenne families!
REGENXBIO Inc. has announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial, and indicated that the company has confirmed an end-of-Phase II meeting is scheduled with the FDA at the end of July. REGENXBIO will be participating in PPMD’s 30th Annual Conference in Orlando, Florida during the “Research Row: Gene Therapy – Current and Evolving Landscape” session on Friday, June 28. If you haven't already registered to attend PPMD's 30th Annual Conference, register to attend virtually! https://lnkd.in/eV8Csijh
-
REGENXBIO announces expansion of AFFINITY DUCHENNE® trial to include a new cohort of younger patients. Learn more: https://lnkd.in/enTeuAAi